ArticleFrontiers in medicine2026
Penile pseudomyogenic hemangioendothelioma: a rare case report with clinicopathologic features and multidisciplinary management.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pseudomyogenic hemangioendothelioma (PHE) is a rare vascular neoplasm of intermediate malignancy that predominantly affects the limbs and trunk of young adults. Genital localization, particularly penile involvement, is exceptionally uncommon and may lead to diagnostic challenges. Case presentation: A 29-year-old man presented with a painful, ulcerative lesion on the ventral prepuce that had been present for 5 years. He initially underwent circumcision, and histopathologic evaluation of the surgical specimen suggested an undifferentiated malignant neoplasm. Despite surgery, symptoms persisted. Three months later, magnetic resonance imaging (MRI) revealed a penile mass infiltrating the corpora cavernosa, corpus spongiosum, and glans. Subsequent histopathologic re-evaluation with immunohistochemistry demonstrated co-expression of cytokeratins and endothelial markers (CD31, ERG), establishing the diagnosis of PHE. The tumor showed perineural and intravascular invasion with positive surgical margins. Given the extent of local disease and the complex anatomic location, a multidisciplinary team evaluated wide local excision, including the possibility of partial penectomy, versus systemic targeted therapy. The patient ultimately underwent partial penile resection, resulting in marked improvement in pain and overall clinical status. Discussion: Penile PHE can mimic other spindle cell neoplasms, necessitating immunohistochemistry for definitive diagnosis. Surgery with negative margins remains the mainstay of treatment, though it may compromise function in genital sites. Targeted therapies directed at FOSB-related molecular pathways may benefit from unresectable or multifocal disease. Conclusion: There are only a limited number of cases reported worldwide of this rare neoplasm, and to our knowledge this represents the first reported case from Ecuador and the first from Latin America involving this anatomic site. It highlights the tumor's diagnostic complexity, potential for aggressive local behavior, and the importance of multidisciplinary management and long-term surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.